Covis Pharma, a specialty pharmaceutical company, markets therapeutic solutions for patients with life threatening and other serious medical conditions. It offers branded and generic pharmaceutical products and injectable in cardiovascular, central nervous system, oncology, and acute care markets.
Covis Pharma’s products include ceftazidime, cefuroxime, digoxin, tranylcypromine sulfate, and ranitidine hydrochloride injection. It also engages in developing therapeutic solutions to improve patients' quality of life in cardiology, CNS (psych and neuro), oncology, and rheumatology sectors.
Dean J. Mitchell founded it in 2011, with its headquarters in Zug in Switzerland. Covis Pharma operates as a subsidiary of Covis Pharma Holdings.